Biweekly administration of low-dose docetaxel in hormone-resistant prostate cancer: Pilot study of an effective subtoxic therapy

Clinical Prostate Cancer

Volumn 2, Issue 1, 2003, Pages 46-49

  Karavasilis, Vasilis ^b   Briasoulis, Evangelos ^a   Siarabi, Olga ^b   Pavlidis, Nicholas ^b  

^a UNIVERSITY OF IOANNINA   (Greece)

^b NONE

Author keywords

Antiandrogen therapy; Chemotherapy; Orchiectomy; Prostate specific antigen; Taxanes

Indexed keywords

ANTIANDROGEN; DEXAMETHASONE; DIMETINDENE; DOCETAXEL; DOXORUBICIN; ESTRAMUSTINE; ETOPOSIDE; GONADORELIN; MITOXANTRONE; PACLITAXEL; PROSTATE SPECIFIC ANTIGEN; RANITIDINE; TAXANE DERIVATIVE; VINCA ALKALOID;

AGED; ALOPECIA; ARTICLE; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CLINICAL ARTICLE; DACRYORRHEA; DRUG DOSE REGIMEN; EDEMA; FATIGUE; HORMONE RESISTANCE; HUMAN; LACRIMAL GLAND DISEASE; LACRIMATION; LOW DRUG DOSE; LUNG EMBOLISM; MALE; METASTASIS; NEUTROPENIA; PERIPHERAL NEUROPATHY; PNEUMONIA; PROSTATE CANCER; THROMBOEMBOLISM; TREATMENT FAILURE;

EID: 0041476099     PISSN: 15400352     EISSN: None     Source Type: Journal    
DOI: 10.3816/CGC.2003.n.012     Document Type: Article

References (29)

1. Potosky AL, Miller BA, Albertsen PC, et al. The role of increasing detection in the rising incidence of prostate cancer. JAMA 1995; 273:548-552.
2. Jemal A, Murray T, Samuels A, et al. Cancer statistics, 2003. CA Cancer J Clin 2003; 53:5-26.
3. Scher HI, Steineck G, Kelly WK. Hormone-refractory (D3) prostate cancer: refining the concept. Urology 1995; 46:142-148.
4. Isaacs JT. The biology of hormone refractory prostate cancer. Why does it develop? Urol Clin North Am 1999; 26:263-273.
5. Rini BI, Small EJ. Hormone-refractory prostate cancer. Curr Treat Options Oncol 2002; 3:437-446.
6. Dawson NA, Conaway M, Halabi S, et al. A randomized study comparing standard versus moderately high dose megestrol acetate for patients with advanced prostate carcinoma: cancer and leukemia group B study 9181. Cancer 2000; 88:825-834.
7. Small EJ, Vogelzang NJ. Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm. J Clin Oncol 1997; 15:382-388.
8. Goodin S, Rao KV, DiPaola RS. State-of-the-art treatment of metastatic hormone-refractory prostate cancer. Oncologist 2002; 7:360-370.
9. Diaz JF, Andreu JM. Assembly of purified GDP-tubulin into microtubules induced by taxol and taxotere: reversibility, ligand stoichiometry, and competition. Biochemistry 1993; 32:2747-2755.
10. Haldar S, Chintapalli J, Croce CM. Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res 1996; 56:1253-1255.
11. Obasaju C, Hudes GR. Paclitaxel and docetaxel in prostate cancer. Hematol Oncol Clin North Am 2001; 15:525-545.
12. Briasoulis E, Karavasilis V, Anastasopoulos D, et al. Weekly docetaxel in minimally pretreated cancer patients: a dose-escalation study focused on feasibility and cumulative toxicity of long-term administration. Ann Oncol 1999; 10:701-706.
13. Bubley GJ, Carducci M, Dahut W, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999; 17:3461-3467.
14. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-216.
15. Cancer Therapy Evaluation Program. Common Toxicity Criteria, Version 2.0. Avaliable at: http://ctep.cancer.gov/forms/CYCv20_4-30-992.pdf. Accessed May 31, 2003.
16. Logothetis CJ. Docetaxel in the integrated management of prostate cancer. Current applications and future promise. Oncology (Huntingt) 2002; 16:63-72.
17. Beer TM, Eilers KM, Garzotto M, et al. Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer. J Clin Oncol 2003; 21:123-128.
18. Picus J, Schultz M. Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: preliminary results. Semin Oncol 1999; 26:14-18.
19. Friedland D, Cohen J, Miller R, Jr., et al. A phase II trial of docetaxel (Taxotere) in hormone-refractory prostate cancer: correlation of antitumor effect to phosphorylation of Bcl-2. Semin Oncol 1999; 26:19-23.
20. Roth BJ, Yeap BY, Wilding G, et al. Taxol in advanced, hormone-refractory carcinoma of the prostate. A phase II trial of the Eastern Cooperative Oncology Group. Cancer 1993; 72:2457-2460.
21. Morris MJ, Santamauro J, Shia J, et al. Fatal respiratory failure associated with treatment of prostate cancer using docetaxel and estramustine. Urology 2002; 60:1111.
22. Beer TM, Pierce WC, Lowe BA, et al. Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer. Ann Oncol 2001; 12:1273-1279.
23. Tannock I, Gospodarowicz M, Meakin W, et al. Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response. J Clin Oncol 1989; 7:590-597.
24. Storlie JA, Buckner JC, Wiseman GA, et al. Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone-refractory metastatic prostate carcinoma. Cancer 1995; 76:96-100.
25. Kelly WK, Curley T, Leibretz C, et al. Prospective evaluation of hydrocortisone and suramin in patients with androgen-independent prostate cancer. J Clin Oncol 1995; 13:2208-2213.
26. Savarese DM, Halabi S, Hars V, et al. Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B. J Clin Oncol 2001; 19:2509-2516.
27. Petrylak DP, Macarthur RB, O'Connor J, et al. Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer. J Clin Oncol 1999; 17:958-967.
28. Kreis W, Budman DR, Fetten J, et al. Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma. Ann Oncol 1999; 10:33-38.
29. Ferrari AC, Chachoua A, Singh H, et al. A Phase I/II study of weekly paclitaxel and 3 days of high dose oral estramustine in patients with hormone-refractory prostate carcinoma. Cancer 2001; 91:2039-2045.